174 related articles for article (PubMed ID: 18500693)
21. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance.
Cantiello F; Russo GI; Cicione A; Ferro M; Cimino S; Favilla V; Perdonà S; De Cobelli O; Magno C; Morgia G; Damiano R
World J Urol; 2016 Apr; 34(4):485-93. PubMed ID: 26194612
[TBL] [Abstract][Full Text] [Related]
22. Quantitative multi-gene expression profiling of primary prostate cancer.
Schmidt U; Fuessel S; Koch R; Baretton GB; Lohse A; Tomasetti S; Unversucht S; Froehner M; Wirth MP; Meye A
Prostate; 2006 Oct; 66(14):1521-34. PubMed ID: 16921506
[TBL] [Abstract][Full Text] [Related]
23. [Does PCA3 score and prostatic MRI help selection of patients scheduled for initial prostatic biopsy?].
Vinet M; Vlaeminck-Guillem V; Rouvière O; Perrin P; Paparel P; Devonec M; Adam E; Briant PE; Ruffion A
Prog Urol; 2013 Feb; 23(2):121-7. PubMed ID: 23352305
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes.
Hendriks RJ; Dijkstra S; Jannink SA; Steffens MG; van Oort IM; Mulders PF; Schalken JA
Clin Chem Lab Med; 2016 Mar; 54(3):483-92. PubMed ID: 26630694
[TBL] [Abstract][Full Text] [Related]
25. Prognostic accuracy of prostate health index and urinary prostate cancer antigen 3 in predicting pathologic features after radical prostatectomy.
Vlaeminck-Guillem V
Urol Oncol; 2015 Nov; 33(11):498. PubMed ID: 26116413
[No Abstract] [Full Text] [Related]
26. Molecular PCA3 diagnostics on prostatic fluid.
van Gils MP; Cornel EB; Hessels D; Peelen WP; Witjes JA; Mulders PF; Rittenhouse HG; Schalken JA
Prostate; 2007 Jun; 67(8):881-7. PubMed ID: 17440939
[TBL] [Abstract][Full Text] [Related]
27. Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection.
Foj L; Milà M; Mengual L; Luque P; Alcaraz A; Jiménez W; Filella X
Clin Chim Acta; 2014 Aug; 435():53-8. PubMed ID: 24803095
[TBL] [Abstract][Full Text] [Related]
28. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
[TBL] [Abstract][Full Text] [Related]
29. Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness.
Tallon L; Luangphakdy D; Ruffion A; Colombel M; Devonec M; Champetier D; Paparel P; Decaussin-Petrucci M; Perrin P; Vlaeminck-Guillem V
Int J Mol Sci; 2014 Jul; 15(8):13299-316. PubMed ID: 25079439
[TBL] [Abstract][Full Text] [Related]
30. Urinary PCA3 to predict prostate cancer in a cohort of 1015 patients.
Vlaeminck-Guillem V; Devonec M; Champetier D; Decaussi-Petrucci M; Paparel P; Perrin P; Ruffion A
Prog Urol; 2015 Dec; 25(16):1160-8, e1-8. PubMed ID: 26376283
[TBL] [Abstract][Full Text] [Related]
31. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
[TBL] [Abstract][Full Text] [Related]
32. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
[TBL] [Abstract][Full Text] [Related]
33. Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers.
Mengual L; Lozano JJ; Ingelmo-Torres M; Izquierdo L; Musquera M; Ribal MJ; Alcaraz A
BMC Cancer; 2016 Feb; 16():76. PubMed ID: 26856686
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of Twist-1, E-cadherin and EZH2 in Prostate Cancer: An Immunohistochemical Study.
Abdelrahman AE; Arafa SA; Ahmed RA
Turk Patoloji Derg; 2017; 1(1):198-210. PubMed ID: 28832071
[TBL] [Abstract][Full Text] [Related]
35. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
36. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
Rhodes DR; Sanda MG; Otte AP; Chinnaiyan AM; Rubin MA
J Natl Cancer Inst; 2003 May; 95(9):661-8. PubMed ID: 12734317
[TBL] [Abstract][Full Text] [Related]
37. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
38. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?
Tombal B; Andriole GL; de la Taille A; Gontero P; Haese A; Remzi M; Speakman M; Smets L; Stoevelaar H
Urology; 2013 May; 81(5):998-1004. PubMed ID: 23523291
[TBL] [Abstract][Full Text] [Related]
39. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG.
Warrick JI; Tomlins SA; Carskadon SL; Young AM; Siddiqui J; Wei JT; Chinnaiyan AM; Kunju LP; Palanisamy N
Mod Pathol; 2014 Apr; 27(4):609-20. PubMed ID: 24072184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
